FindTrial
Sign In

KEYTRUDA® (pembrolizumab)

DRUG7 trials

Sponsors

Lyvgen Biopharma Holdings Limited, Qurient Co., Ltd., Phanes Therapeutics, Xencor, Inc., Dragonfly Therapeutics

Conditions

Advanced CancerBiliary Tract Cancer (BTC)CancerCastration-resistant Prostate CancerColorectal CancerGastric or Gastroesophageal Junction AdenocarcinomaHead and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal Melanoma

Phase 1

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Active, not recruitingNCT04130542
Lyvgen Biopharma Holdings LimitedCancer
Start: 2019-10-31End: 2025-12-31Target: 276Updated: 2024-10-31
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
RecruitingNCT05394103
Qurient Co., Ltd.Advanced Cancer, Metastatic Cancer
Start: 2022-08-30End: 2026-08-30Target: 130Updated: 2025-08-17
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RecruitingNCT05482893
Phanes TherapeuticsBiliary Tract Cancer (BTC), Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Start: 2023-03-15End: 2028-04-30Target: 258Updated: 2025-11-04
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
CompletedNCT05585034
Xencor, Inc.Castration-resistant Prostate Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma +6
Start: 2022-12-14End: 2025-05-20Updated: 2025-08-07
Study of DF9001 in Patients With Advanced Solid Tumors
CompletedNCT05597839
Dragonfly TherapeuticsSolid Tumor, Adult
Start: 2022-11-15End: 2025-08-15Updated: 2025-10-29
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
TerminatedNCT05996445
Xencor, Inc.Solid Tumors
Start: 2023-07-28End: 2024-05-21Updated: 2024-08-23
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
RecruitingNCT07158918
ABL Bio, Inc.Solid Tumors
Start: 2025-08-06End: 2027-12-02Target: 65Updated: 2025-09-08

Related Papers

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
Journal of Clinical Oncology2026-01-10
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
Journal of Clinical Oncology2024-06-012 citations
Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.
Journal of Clinical Oncology2024-06-01
First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2023-06-012 citations
Abstract 5977: Evaluation of the potential combination regimens for q901, a clinical stage selective cdk7 inhibitor, as a DNA damage repair inhibitor
Cancer Research2023-04-04
Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.
Journal of Clinical Oncology2021-05-207 citations